ClinicalTrials.gg
CompletedNCT04128969Updated Nov 2, 2026

Causal Mechanisms in Adolescent Arterial Stiffness

A Phase 2 interventional study of CS+ and CS- in Lipid Disorder, Dyslipidemias and Aortic Stiffness, sponsored by Baylor College of Medicine. Completed at 1 site in United States. Open to participants aged 11 Years to 21 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Primary conditionDyslipidemiasRegistry: Lipid Metabolism DisordersReclassifiedWhy we changed it
Registry
Lipid Metabolism Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Dyslipidemias
Why
  1. The study's listed conditions name Dyslipidemias, a narrower term within Lipid Metabolism Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Baylor College of Medicine · Phase 2, Interventional, and Treatment

How we know

Updated Nov 2, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
11 Years to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 349 studies in Dyslipidemias with a site in United States — 23 open to participants now, 34 under way, 6 of them phase 3. Dyslipidemias · United States.

Enrollment
189th of 316
72 · median 105
Started
2020
with 12 others
Phase 2
66 of 349
2 open now
Registered
259th of 349
by date

Among the 349 studies in Dyslipidemias with a site in United States, this one is the 189th largest by enrollment of the 316 interventional ones that give a count, is one of 13 that started in 2020, is one of 66 in phase 2, and was the 259th registered.

Dyslipidemias

1,251 studies on the registry are indexed under Dyslipidemias; 178 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

23 of the 349 studies in Dyslipidemias with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 11 Years to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 349 studies in Dyslipidemias with a site in United States, or all of them as a file.
02

Study summary

Hardening of the blood vessels, called arterial stiffness, is a risk factor for future heart disease and its causes are unclear. The proposed study will 1) randomly assign adolescents at high risk of stiffening blood vessels to take a protein supplement called carnitine and study its effects on arterial stiffening and 2) study carnitine related genes for their effect on arterial stiffening. The study will definitively establish a role for carnitine action as a cause of stiffening blood vessels and signal a way to treat or prevent stiffening.

Read the detailed description

Aortic stiffness measured in adolescence or adulthood determines current hypertension, predicts future incidence of hypertension, and future atherosclerotic cardiovascular disease (ASCVD) events. International hypertension guidelines list severe aortic stiffness as grounds to intensify anti-hypertensive pharmacotherapy. Mechanisms of arterial stiffness beyond aging and obesity warrant further elucidation. In our preliminary data from adolescents attending weight-loss summer camps arterial stiffness improvement was not associated with weight change but was with change in circulating carnitine. Carnitine influences fatty acid oxidation and carbohydrate metabolism. Carnitine could therefore link to arterial stiffness through insulin resistance which in turn affects cellular tone, vascular fibrosis, modification of lipids or glucose metabolism, and/or advanced glycation end products. This proposal leverages 2 instrumental variable study designs to infer a causal relation between carnitine and arterial stiffness. First, in 90 youth 11-21 years old at risk of arterial stiffening due to high serum triglycerides(TG), we will conduct a mechanistic, double blinded, randomized controlled trial for the effect of 6 months of oral carnitine supplementation (CS+, n=45) versus placebo (CS-, n=45) on aortic stiffness measured as carotid femoral pulse wave velocity (CFPWV); serum fatty acid oxidation biomarkers by metabolomics analysis; insulin resistance as homeostatic model assessment of insulin resistance (HOMA-IR); and TG. Aim 1 is to compare CS+ versus CS- on change in arterial stiffness and monitor adverse events. The hypothesis CS+ is associated with lower arterial stiffening, and CS+ effect is not modified by sex or race/ethnicity. Aim 2 is to compare the effect of CS+ versus CS- on fatty acid metabolism, insulin resistance, and lipids. The hypothesis is that CS+ alters long chain fatty acid beta oxidation, measured as lower long chain acylcarnitines, which in turn improves (HOMA-IR), and in turn decreases TG levels. This causal chain will be disentangled for direct versus indirect effects on CFPWV change. Second, naturally randomly assorted carnitine single nucleotide polymorphisms (SNPs) noted above will be used to characterize the relationship of carnitine to arterial stiffness and stratify the effectiveness of CS+.Aim 3a is to obtain the direct effect of carnitine on arterial stiffness using Mendelian randomization of SNPs associated with serum carnitine as instrumental variables with the hypothesis these variant SNPs are associated with lower arterial stiffness, supporting a causal inference. Aim 3b is to identify effect modification of CS+ vs CS- on arterial stiffness by examining if a carnitine genetic risk score will modify the effect of CS+ on change in arterial stiffness. This proposal with 2 instrumental variable projects would evaluate a causal role for carnitine in arterial stiffness at a point when the life course trajectory to hypertension can be modified. The study will also investigate the role of carnitine in insulin resistance and dyslipidemia at this same age, which may serve as grounds for future therapeutic clinical trials. Discovering genetically mediated causes of arterial stiffness or other outcomes may facilitate targeting of future therapies on susceptible youth before atherosclerotic changes are irreversible.

03

Conditions studied

  • Lipid Disorder
  • Dyslipidemias
  • Aortic Stiffness
  • Insulin Resistance Syndrome
  • Metabolic Syndrome
  • Pediatric Obesity

Keywords

  • dyslipidemia
  • arterial stiffness
  • pediatric obesity
  • metabolic syndrome
  • insulin resistance
04

In context

Dyslipidemias Reclassified

1,251 studies on the registry are indexed under Dyslipidemias; 178 are open to participants now.

This study's enrollment of 72 is below the median of 100 across 988 interventional studies indexed under Dyslipidemias.

Browse Dyslipidemias studies →

Lead sponsor

Baylor College of Medicine is the lead sponsor of 747 studies on the registry; 110 are open to participants now.

Of its 84 completed or terminated interventional studies of FDA-regulated products, 45 (54%) have results posted.

Compared within Dyslipidemias, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lipid Metabolism Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
11 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 11-21 year old adolescents
  2. males and females
  3. all ethnicities and races
  4. fasting serum triglyceride levels over 130 and less than 500 mg/dL
  5. fasting low density lipoprotein cholesterol (LDL-C) less than 160mg/dL.

Exclusion criteria

Exclusion Criteria:

  1. known seizure disorder
  2. renal failure patients requiring renal replacement therapy like dialysis or renal transplant
  3. diabetes mellitus type 1 or 2
  4. congenital heart disease requiring surgical or catheterization intervention
  5. current pregnancy or planned pregnancy during the active study participation
  6. incarceration/institutionalized/wards of the state
  7. known metabolic disorders that require carnitine therapy
  8. nonadherence to study protocol during run-in phase defined as possessing 25% more than the expected remainder of placebo supplement pro-rated to the day of assessment
06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Carnitine supplementation (CS+)

    Carnitine supplementation in liquid form, sugar free.

    Dietary Supplement: CS+

  • Placebo comparator
    Placebo (CS-)

    Placebo comparator liquid similar in appearance and taste to CS+.

    Dietary Supplement: CS-

Interventions

  • Dietary supplementCS+

    Oral carnitine supplementation

  • Dietary supplementCS-

    Placebo

07

What researchers measure

Primary outcomes

  1. Change in Carotid Femoral Pulse Wave Velocity

    Carotid Femoral Pulse Wave Velocity will be measured noninvasively using applanation tonometry.

    Time frame: 6 months

Secondary outcomes

  1. Change in Fasting Triglyceride

    Fasting serum triglycerides to be measured using conventional techniques.

    Time frame: 6 months

  2. Change in Insulin Resistance

    Insulin resistance will be assessed using fasting serum glucose and fasting serum insulin to calculate homeostatic model assessment of insulin resistance.

    Time frame: 6 month

08

Study locations

1 site
  • Texas Children's Hospital
    Houston, Texas 77030, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in Jul 2026, 77 months.

Of 43 phase 2 interventional studies under Dyslipidemias, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 21. This study's 77 months is above that.

Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jul 2026, on Nov 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2019
First posted
Oct 16, 2019
StartActual
Feb 1, 2020
Primary completionActual
Jul 1, 2026was Jun 2026
CompletionActual
Aug 31, 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 2, 2026
Primary completion
Jun 1, 2026→Jul 1, 2026 (actual)
Nov 2, 2026
Enrollment
90 (estimated)→72 (actual)
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Active, not recruiting→Completed
    Primary completion Jun 1, 2026→Jul 1, 2026 (now actual)
    Enrollment 90 (estimated)→72 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04128969
Responsible party
Justin Zachariah (Principal Investigator. Assistant Professor in Pediatrics, Baylor College of Medicine) — Principal investigator
First posted
Oct 16, 2019
Start date
Feb 1, 2020
Primary completion
Jul 1, 2026
Completion
Aug 31, 2026
Last update
Nov 2, 2026

Study contacts

Justin P Zachariah, MD MPH
principal investigator · Study Principal Investigator

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion